Clinical trials: Takayasu Arteritis
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2.
- Conditions
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- Trial name
- NCT05388682
- Testing
- Percutaneous transluminal pulmonary angioplasty
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Takayasu Arteritis, Large Vessel Vasculitis
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion.
- Trial name
- STARS (NCT07477795)
- Testing
- Secukinumab, Standard of Care (SOC)
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Takayasu Arteritis
Registration Study of Takayasu's Arteritis in China
Takayasu arteritis(TA) is a chronic progressive vasculitis predominantly affecting the aorta and its major branches. The demographic, clinical and prognostic features of Takayasu arteritis in China remains in uncertainties.
- Trial name
- TA-China (NCT03199183)
- Testing
- PET-CT, laboratory biomarker analysis, genetic sequencing
- Where
- China
- Volunteers
- 1,067 people, healthy volunteers welcome
- Sponsor
- China National Center for Cardiovascular Diseases
Takayasu Arteritis, Methotrexate
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy.
- Conditions
- Takayasu Arteritis, Methotrexate, Inhibition, Treatment
- Trial name
- NCT04299971
- Testing
- Methotrexate Tablets, Tofacitinib tablet
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Shanghai Zhongshan Hospital
Takayasu's Arteritis, Giant Cell Arteritis
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms.
- Trial name
- NCT00556439
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Takayasu Arteritis, Cardiovascular Diseases
Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study
This nationwide observational cohort study compares the risk of major adverse cardiovascular events (MACE) and territory-specific arterial complications between patients with incident Takayasu arteritis and matched…
- Trial name
- TAK-CV-2026 (NCT07686991)
- Where
- 2 sites in France
- Volunteers
- 8,275 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Takayasu Arteritis
Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis
The purpose of this study is to demonstrate that [18F]FDG PET is a a better method than clinical and laboratory values for the identification and assessment of inflammatory activity in patients with Takayasu Arteritis (TA)…
- Trial name
- NCT01532167
- Where
- Mexico
- Volunteers
- 26 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
TAKAYASU ARTERITIS
China Takayasu Arteritis Registry (CTA Registry)
Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done.
- Trial name
- NCT02964364
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Aimin Dang
Systemic Lupus, Rheumatoid Arthritis
Yellow Fever Vaccine in Patients With Rheumatic Diseases
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans.
- Conditions
- Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy
- Trial name
- NCT03430388
- Testing
- Yellow Fever vaccine (17D)
- Where
- Brazil
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Takayasu Arteritis, Anti-Inflammatory Agents
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
Currently, the traditional disease activity of Takayasu arteritis is mainly based on National Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment.
- Trial name
- ATITA (NCT03550781)
- Testing
- Prednisone, cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Takayasu Arteritis (TAK)
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
- Trial name
- SELECT-TAK (NCT04161898)
- Testing
- Upadacitinib, Prednisolone
- Where
- 48 sites in Argentina, Brazil and 4 more
- Volunteers
- 56 people
- Sponsor
- AbbVie
Behcet's Disease, Churg-Strauss Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
The purpose of this study is to provide validation of patient-reported data in the VCRC Patient Contact Registry by comparing patient-reported data with data provided by the physician who is the primary provider caring for the…
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis
- Trial name
- NCT02190942
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of South Florida
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Takayasu Arteritis, Tocilizumab
A Pilot Study in Severe Patients With Takayasu Arteritis.
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe.
- Conditions
- Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
- Trial name
- NCT04300686
- Testing
- Tocilizumab, Adalimumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Takayasu's Arteritis
Exercise in Juvenile Takayasu Disease
Juvenile Takayasu disease is characterized by chronic inflammation that leads to vascular disease. Exercise may render anti-inflammatory effects and protect against cardiovascular events.
- Trial name
- NCT03494062
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- University of Sao Paulo
Takayasu's Arteritis
Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis
Takayasu's arteritis is a rare disorder that causes swelling and damage to the large arteries in the body, such as the aorta. In order to ensure proper treatment, measuring disease activity is critical.
- Trial name
- NCT00315471
- Where
- 9 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- University of Pennsylvania
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Arteritis, Takayasu
The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis
Takayasu Arteritis (TA) affects medium and large caliber arteries causing stenosis, occlusion or aneurysms. It has great predilection for the aortic arch, subclavian and extracranial arteries.
- Trial name
- NCT03654222
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez